Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature reviews. Drug discovery

• Publication date

  2012-03-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrd2909PMID 22460124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Mechanisms of action of intravenous immunoglobulins].

  2012cited by this paper
• Regulation of human neutrophil Fcγ receptor IIa by C5a receptor promotes inflammatory arthritis in mice.

  2011cited by this paper
• Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

  2011cited by this paper
• The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders.

  2011cited by this paper
• Immunoglobulin A

  2011cited by this paper
• Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

  2011cited by this paper
• Targeting FcαRI on Polymorphonuclear Cells Induces Tumor Cell Killing through Autophagy

  2011cited by this paper
• An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

  2011cited by this paper
• Inhibitory ITAM Signaling Traps Activating Receptors with the Phosphatase SHP-1 to Form Polarized “Inhibisome” Clusters

  2011cited by this paper
• Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8−CD11b+ dendritic cells

  2011cited by this paper
• Structural Basis for FcγRIIa Recognition of Human IgG and Formation of Inflammatory Signaling Complexes

  2011cited by this paper
• Modulation of antibody effector function.

  2011cited by this paper
• Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies

  2011cited by this paper
• Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway

  2011cited by this paper
• Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

  2011cited by this paper
• Crystal Structure of Fcγ Receptor I and Its Implication in High Affinity γ-Immunoglobulin Binding*

  2011cited by this paper
• Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.

  2011cited by this paper
• Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy.

  2010cited by this paper
• Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• In vivo veritas: the surprising roles of Fc receptors in immunity

  2010cited by this paper
• Transgenic mice expressing human FcgammaRIIa have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells.

  2010cited by this paper
• CD23/FcεRII: molecular multi‐tasking

  2010cited by this paper
• Copy number, linkage disequilibrium and disease association in the FCGR locus

  2010cited by this paper
• Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

  2010cited by this paper
• Generation of a high-affinity Fcgamma receptor by Ig-domain swapping between human CD64A and CD16A.

  2010cited by this paper
• FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications

  2010cited by this paper
• Antibody‐mediated modulation of immune responses

  2010cited by this paper
• Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations†

  2010cited by this paper
• Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy

  2010cited by this paper
• X-ray Crystal Structures of Monomeric and Dimeric Peptide Inhibitors in Complex with the Human Neonatal Fc Receptor, FcRn

  2010cited by this paper
• IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.

  2010cited by this paper
• FcγRIIb Inhibits Allergic Lung Inflammation in a Murine Model of Allergic Asthma

  2010cited by this paper
• FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications

  2010cited by this paper
• Mechanisms of action of intravenous immunoglobulins

  2010cited by this paper
• In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

  2010cited by this paper
• Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG.

  2010cited by this paper
• Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system

  2010cited by this paper
• Evolution of anti- CD20 monoclonal antibody therapeutics in oncology

  2010cited by this paper
• Inhibition of destructive autoimmune arthritis in FcγRIIa transgenic mice by small chemical entities

  2009cited by this paper
• A Critical evaluation of different methods of recording centric jaw relation of completely edentulous Individuals: An In Vivo study

  2009cited by this paper
• Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human FcγRI

  2009cited by this paper
• Glycosylation as a strategy to improve antibody-based therapeutics

  2009cited by this paper
• Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.

  2009cited by this paper
• A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population

  2009cited by this paper
• Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

  2009cited by this paper
• Recombinant Soluble Human FcγR1A (CD64A) Reduces Inflammation in Murine Collagen-Induced Arthritis1

  2009cited by this paper
• Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action.

  2009cited by this paper
• Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

  2009cited by this paper
• Identification of a High Affinity FcγRIIA-binding Peptide That Distinguishes FcγRIIA from FcγRIIB and Exploits FcγRIIA-mediated Phagocytosis and Degradation*

  2009cited by this paper
• Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.

  2009cited by this paper
• FcγRIIB Deficiency Leads to Autoimmunity and a Defective Response to Apoptosis in Mrl-MpJ Mice1

  2008cited by this paper
• Amelioration of collagen-induced arthritis by human recombinant soluble FcgammaRIIb.

  2008cited by this paper
• Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci

  2008cited by this paper
• Regulation of hematopoietic cell function by inhibitory immunoglobulin G receptors and their inositol lipid phosphatase effectors

  2008cited by this paper
• Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcgamma receptors and can be effectively blocked by decoy Fcgamma receptors.

  2008cited by this paper
• Fcγ receptors as regulators of immune responses

  2008cited by this paper
• Targeting Immune Complex-Mediated Hypersensitivity with Recombinant Soluble Human FcγRIA (CD64A)1

  2008cited by this paper
• In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner

  2008cited by this paper
• Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice.

  2008cited by this paper
• Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.

  2008cited by this paper
• Differential Contribution of Three Activating IgG Fc Receptors (FcγRI, FcγRIII, and FcγRIV) to IgG2a- and IgG2b-Induced Autoimmune Hemolytic Anemia in Mice1

  2008cited by this paper
• An FcgammaRIIa-binding peptide that mimics the interaction between FcgammaRIIa and IgG.

  2008cited by this paper
• Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer.

  2008cited by this paper
• Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases.

  2008cited by this paper
• Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors

  2008cited by this paper
• An FcγRIIa-binding peptide that mimics the interaction between FcγRIIa and IgG

  2008cited by this paper
• Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).

  2008cited by this paper
• Fcgamma receptors as regulators of immune responses.

  2008cited by this paper
• Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis.

  2007cited by this paper
• Expression Profile of FcγRIIb on Leukocytes and Its Dysregulation in Systemic Lupus Erythematosus1

  2007cited by this paper
• Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

  2007cited by this paper
• Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus.

  2007cited by this paper
• Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy

  2007cited by this paper
• CD16 promotes Escherichia coli sepsis through an FcRγ inhibitory pathway that prevents phagocytosis and facilitates inflammation

  2007cited by this paper
• Pivotal Involvement of Fcγ Receptor IIA in the Neutralization of Lipopolysaccharide Signaling via a Potent Novel Anti-TLR4 Monoclonal Antibody 15C1*

  2007cited by this paper
• Systemic lupus erythematosus-associated defects in the inhibitory receptor FcγRIIb reduce susceptibility to malaria

  2007cited by this paper
• Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1.

  2007cited by this paper
• Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32)

  2007cited by this paper
• FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity

  2007cited by this paper
• Inhibition of Immune Responses by ITAM-Bearing Receptors

  2006cited by this paper
• A synthetic mimic of human Fc receptors: defined chemical modification of cell surfaces enables efficient endocytic uptake of human immunoglobulin-G.

  2006cited by this paper
• Characterization of an FcγRI-binding peptide selected by phage display

  2006cited by this paper
• FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.

  2006cited by this paper
• Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies

  2006cited by this paper
• FcR-Bearing Myeloid Cells Are Responsible for Triggering Murine Lupus Nephritis1

  2006cited by this paper
• Cutting Edge: Inhibition of TLR and FcR Responses in Macrophages by Triggering Receptor Expressed on Myeloid Cells (TREM)-2 and DAP121

  2006cited by this paper
• FcγRIIa, Not FcγRIIb, Is Constitutively and Functionally Expressed on Skin-Derived Human Mast Cells1

  2006cited by this paper
• R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

  2006cited by this paper
• Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells.

  2006cited by this paper
• Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.

  2006cited by this paper
• Surface‐bound anti–type II collagen–containing immune complexes induce production of tumor necrosis factor α, interleukin‐1β, and interleukin‐8 from peripheral blood monocytes via fcγ receptor IIA: A potential pathophysiologic mechanism for humoral anti–type II collagen immunity in arthritis

  2006cited by this paper
• The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms.

  2006cited by this paper
• Characterization of an FcgammaRI-binding peptide selected by phage display.

  2006cited by this paper
• Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy

  2006cited by this paper
• Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells

  2006cited by this paper
• Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

  2006cited by this paper
• Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthr

  2006cited by this paper
• CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.

  2006cited by this paper
• Alteration of the FcγRIIa Dimer Interface Affects Receptor Signaling but Not Ligand Binding1

  2006cited by this paper
• Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II

  2006cited by this paper

• Advancing immunotherapy via multiple immune cells co-engagement

  2026cites this paper
• Autoantibodies as Precision Tools in Connective Tissue Diseases: From Epiphenomenon to Endophenotype

  2026cites this paper
• Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies

  2025cites this paper
• FcγRIIa in autoimmunity: Unraveling pathogenic mechanisms and therapeutic opportunities.

  2025cites this paper
• FcRγ-dependent NK cell licensing through CD244 promotes antitumour immunity.

  2025cites this paper
• Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

  2025cites this paper
• Site-specific adaptive nanovesicles for oral insulin delivery

  2025cites this paper
• FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs

  2025cites this paper
• Patterned Antigens on DNA Origami Controls the Structure and Cellular Uptake of Immune Complexes.

  2025cites this paper
• Monoclonal antibodies - A repertoire of therapeutics.

  2025cites this paper
• Cell Surface Markers of HIV Latency: Current Insights and Future Directions

  2025cites this paper
• Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants

  2025cites this paper
• High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19

  2025cites this paper
• Targeting phagocytosis checkpoints for cancer immunotherapy

  2025influential citation
• Affinity maturation and optimization of CD44v6-targeting antibodies for molecular radiotherapy.

  2025cites this paper
• Outperforming Biorecognition: Epitope-Imprinted Nanoparticle Enables High-Species-Specificity Purification of Human IgG.

  2025cites this paper
• Advances in Targeted Therapies for Rehumatiod Arthritis: From Biologic to Small Molecule Inhibitors

  2025cites this paper
• Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects

  2025cites this paper
• Different antibody isotypes against tuberculosis: what we know and what we need to know

  2025cites this paper
• Preclinical assessment of two FcγRI-specific antibodies that competitively inhibit immune complex-FcγRI binding to suppress autoimmune responses

  2025cites this paper
• Intravenous immunoglobulin (IVIg) ameliorates disease in a murine model of anti-laminin 332 mucous membrane pemphigoid.

  2024cites this paper
• Structural insights into the high-affinity IgE receptor FcεRI complex

  2024cites this paper
• Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs

  2024cites this paper
• Development of a Time-Resolved Fluorescence Resonance Energy Transfer ultra-high throughput screening assay for targeting SYK and FCER1G interaction

  2024cites this paper
• Development of a Time-Resolved Fluorescence Resonance Energy Transfer ultra-high throughput screening assay targeting SYK and FCER1G interaction.

  2024cites this paper
• IGSF9 promotes tumor invasion and metastasis through GSK-3β/β-catenin mediated EMT in lung cancer

  2024cites this paper
• Characterization of a primary cellular airway model for inhalative drug delivery in comparison with the established permanent cell lines CaLu3 and RPMI 2650

  2024cites this paper
• Stellabody: A novel hexamer‐promoting mutation for improved IgG potency

  2024cites this paper
• Dual-Site Biomimetic Cu/Zn-MOF for Atopic Dermatitis Catalytic Therapy via Suppressing FcγR-Mediated Phagocytosis.

  2024cites this paper
• Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections.

  2024cites this paper
• Fc Proteoforms of ACPA IgG Discriminate Autoimmune Responses in Plasma and Synovial Fluid of Rheumatoid Arthritis Patients and Associate with Disease Activity

  2024cites this paper
• The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancer

  2024cites this paper
• “Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunity

  2024cites this paper
• New immune cell engagers for cancer immunotherapy

  2024cites this paper
• Cellular Membrane-Derived Nanovesicles Expressing hCD64 for Targeting Prostate Cancer.

  2024cites this paper
• The Role of Fc Receptors in the Innate Immune System of Flounders Purported to Be Homologs of FcγRII and FcγRIII.

  2024cites this paper
• TMT-proteomics reveals the therapeutic effects of Lianling decoction against atopic dermatitis through Staphylococcus aureus infection

  2024cites this paper
• Comprehensive insights into rheumatoid arthritis: Pathophysiology, current therapies and herbal alternatives for effective disease management

  2024cites this paper
• NK Cytotoxicity Mediated by NK-92 Cell Lines Expressing Combinations of Two Allelic Variants for FCGR3

  2024cites this paper
• AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors.

  2023cites this paper
• ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1

  2023cites this paper
• Tumor-derived systems as novel biomedical tools—turning the enemy into an ally

  2023cites this paper
• Modulating antibody effector functions by Fc glycoengineering.

  2023cites this paper
• DiPPI: A Curated Data Set for Drug-like Molecules in Protein–Protein Interfaces

  2023cites this paper
• Sepsis – it is all about the platelets

  2023cites this paper
• Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations

  2023cites this paper
• The CD16 and CD32b Fc-gamma receptors regulate antibody-mediated responses in mouse natural killer cells.

  2023cites this paper
• Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity

  2023cites this paper
• Crosstalk between myeloid and B cells shapes the distinct microenvironments of primary and secondary liver cancer.

  2023cites this paper
• Combined polymorphisms involving the IgG heavy chain and fc gamma receptors among Fulani and non-Fulani in Benin: Implications for the natural protection of young Fulani against plasmodium. Falciparum malaria infections.

  2023cites this paper
• Impact of Fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma

  2023cites this paper
• The clarifying lens of cryo‐electron microscopy in immunoglobulin M biology

  2023cites this paper
• Comparative Analysis of FCGR Gene Polymorphism in Pulmonary Sarcoidosis and Tuberculosis

  2023cites this paper
• Low and high serum IgG associates with respiratory infections in a young and working age population

  2023cites this paper
• IgG1 Is the Optimal Subtype for Treating Atherosclerosis by Inducing M2 Macrophage Differentiation, and Is Independent of the FcγRIIA Gene Polymorphism

  2023cites this paper
• Noncovalent antibody catenation on a target surface greatly increases the antigen-binding avidity

  2023cites this paper
• Mutation of the TGN1412 anti‐CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super‐agonist activity

  2023influential citation
• Emerging phagocytosis checkpoints in cancer immunotherapy

  2023cites this paper
• Allosteric synthetic antibody (Allo-SyAb) for improved cancer immunotherapy

  2023cites this paper
• BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

  2023cites this paper
• Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

  2023cites this paper
• Inhibitory Fc-Gamma IIb Receptor Signaling Induced by Multivalent IgG-Fc Is Dependent on Sialylation

  2023cites this paper
• A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose

  2022cites this paper
• CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition.

  2022cites this paper
• Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies

  2022cites this paper
• Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis

  2022cites this paper
• Targeted protein degradation using the lysosomal pathway.

  2022cites this paper
• Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?

  2022cites this paper
• Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer

  2022cites this paper
• Antibody Diversity in Cancer: Translational Implications and Beyond

  2022cites this paper
• Noncovalent antibody catenation on a target surface drastically increases the antigen-binding avidity

  2022cites this paper
• Lipopolysaccharide from Porphyromonas gingivalis, but Not from Porphyromonas endodontalis, Induces Macrophage M1 Profile

  2022cites this paper
• FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus

  2022cites this paper
• Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma

  2022cites this paper
• A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcγR Complex Formation After Vaccination

  2022cites this paper
• The CD3ζ adaptor structure determines functional differences between human and mouse CD16 Fc receptor signaling

  2022cites this paper
• Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era

  2022cites this paper
• Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking

  2022cites this paper
• Affinity capillary electrophoresis – mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner

  2022influential citation
• The Contribution of Liver Sinusoidal Endothelial Cells to Clearance of Therapeutic Antibody

  2022cites this paper
• BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells

  2022cites this paper
• Relative quantitation of glycans in cetuximab using ultra-high-performance liquid chromatography-high-resolution mass spectrometry by Pronase E digestion.

  2022cites this paper
• Preclinical Evaluation of CD64 As a Potential Target For CAR-T-cell Therapy For Acute Myeloid Leukemia

  2021cites this paper
• Application of Nano Drug Delivery Systems in Inhibition of Tumors and Cancer Stem Cells

  2021cites this paper
• The Functional Role of IgA in the IgM/IgA-Enriched Immunoglobulin Preparation Trimodulin

  2021cites this paper
• Bi-modular fusion proteins, a versatile therapeutic tool for re-directing a pre-existing Epstein-Barr virus antibody response towards defined target cells

  2021cites this paper
• An afucosylated anti-CD32b monoclonal antibody induced platelet-mediated adverse events in a human Fcγ receptor transgenic mouse model and its potential human translatability.

  2021cites this paper
• Insight for Immunotherapy of HCMV Infection

  2021cites this paper
• IgG Immune Complexes Inhibit Naïve T Cell Proliferation and Suppress Effector Function in Cytotoxic T Cells

  2021cites this paper
• Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2

  2021cites this paper
• Immune environment of the brain in schizophrenia and during the psychotic episode: A human post-mortem study

  2021cites this paper
• A neurovascular-unit-on-a-chip for the evaluation of the restorative potential of stem cell therapies for ischaemic stroke

  2021cites this paper
• Idiopathic pulmonary fibrosis associated with circulating autoantibodies: a Chinese cohort of a long-term follow-up study

  2021cites this paper
• Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice

  2021cites this paper
• Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy

  2021cites this paper
• A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351

  2021cites this paper
• Improved HIV-positive infant survival is correlated with high levels of HIV-specific ADCC activity in multiple cohorts

  2021cites this paper
• Glycosylation of Therapeutic Proteins: A Critical Quality Attribute.

  2021cites this paper
• Biomarkers for Targeting the HIV-1 Reservoirs

  2021cites this paper
• Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection

  2021cites this paper